Is Metoprolol Effective for Hypertension?
Yes, metoprolol is an effective antihypertensive agent with proven efficacy in lowering blood pressure, though it is no longer recommended as a first-line therapy for uncomplicated hypertension in most patients.
Evidence for Antihypertensive Efficacy
Metoprolol has demonstrated clear blood pressure-lowering effects in controlled clinical trials. In controlled studies, metoprolol at oral dosages of 100 to 450 mg daily has been shown to be an effective antihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics 1. The drug has proven as effective as propranolol, methyldopa, and thiazide-type diuretics in comparative trials, with equal efficacy in both supine and standing positions 1.
In elderly hypertensive patients (60-75 years), metoprolol 100 mg once daily achieved responder rates (diastolic BP ≤95 mm Hg) of 50% at 4 weeks and 65% at 8 weeks, comparable to hydrochlorothiazide 2. Even lower doses show efficacy: metoprolol CR/ZOK 50 mg once daily produced significant reductions in blood pressure in both younger patients with mild hypertension and elderly patients with mild-to-moderate hypertension 3.
Current Guideline Positioning
Despite its efficacy, beta-blockers including metoprolol are no longer recommended as first-line agents for uncomplicated hypertension in current guidelines 4. The 2020 International Society of Hypertension guidelines list beta-blockers as a fifth-line option, to be added only after ACE inhibitors/ARBs, calcium channel blockers, thiazide diuretics, and spironolactone have been tried 4. The 2024 ESC guidelines similarly position beta-blockers as add-on therapy for resistant hypertension, specifically recommending bisoprolol or doxazosin 4.
The 2017 ACC/AHA guidelines recommend thiazide diuretics, calcium channel blockers, ACE inhibitors, or ARBs as first-line agents for most patients without compelling indications 4. In Black patients, beta-blockers and renin-angiotensin system inhibitors are less effective at lowering blood pressure, making thiazide diuretics and calcium channel blockers the preferred first-line agents 4.
Compelling Indications Where Metoprolol IS Recommended
Metoprolol remains a preferred agent when hypertension coexists with specific cardiovascular conditions:
Heart Failure with Reduced Ejection Fraction
Among beta-blockers, carvedilol, metoprolol succinate, and bisoprolol have been shown to improve outcomes in heart failure and are effective in lowering blood pressure 4. These three specific formulations are recommended as Class I therapy for all stable patients with current or prior symptoms of heart failure and reduced LVEF 4. The MERIT-HF trial demonstrated a 34% reduction in mortality with metoprolol succinate in heart failure patients 4.
Post-Myocardial Infarction
Oral beta-blockers should be initiated in the first 24 hours in patients with STEMI who do not have signs of heart failure, evidence of low output state, increased risk for cardiogenic shock, or other contraindications 4. Metoprolol reduced 3-month mortality by 36% in patients with suspected or definite myocardial infarction 1. Beta-blockers should be continued during and after hospitalization for all patients with STEMI and with no contraindications 4.
Stable Ischemic Heart Disease
For patients with stable ischemic heart disease and hypertension, beta-blockers are recommended as first-line therapy because of their effectiveness in preventing angina, improving exercise tolerance, and preventing coronary events 4. GDMT beta-blockers for SIHD that are effective in lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol, and timolol 4.
Limitations and Concerns
Several factors explain the downgrading of beta-blockers for uncomplicated hypertension:
- Beta-blockers exert a relatively weak effect in reducing stroke compared to placebo and show worse outcomes compared to other drug classes, particularly regarding stroke prevention 5
- They demonstrate suboptimal blood pressure lowering compared to other agents and may fail to lower central aortic pressure adequately 5
- Some beta-blockers have unfavorable metabolic effects, though extended-release carvedilol resulted in lower triglycerides, insulin, and C-peptide levels compared with extended-release metoprolol 6
- The COMMIT/CCS-2 trial showed that early intravenous metoprolol followed by high-dose oral therapy had a neutral effect on combined endpoints, with significantly higher rates of cardiogenic shock, especially in patients >70 years, systolic BP <120 mm Hg, or heart rate >110 bpm 4
Important Caveats
Avoid metoprolol in patients with signs of heart failure, low output state, increased risk of cardiogenic shock, prolonged first-degree or high-grade AV block, or reactive airways disease 4. Risk factors for cardiogenic shock include age >70 years, systolic BP <120 mm Hg, sinus tachycardia >110 bpm or heart rate <60 bpm, and increased time since onset of symptoms 4.
Note the critical distinction between metoprolol formulations: metoprolol succinate (extended-release) is the formulation proven to reduce mortality in heart failure, not metoprolol tartrate 4. For hypertension with compelling cardiac indications, use metoprolol succinate 25-50 mg initially, titrating to a daily dose of 200 mg as tolerated 4.